Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ovarianepithelialcarboplatinchemotherapypatients
  Phrases that lowered it: mesenchymalobjectiverelevantin clinicalweeks before
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 11.1% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 19.5% (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 90.9% (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer NCT01145430 · started 2010 · scored riskier than 30% of active trials completed
• Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer NCT00814086 · started 2009 · scored riskier than 43% of active trials completed
• Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery NCT01533207 · started 2012 · scored riskier than 44% of active trials terminated
• EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT01489371 · started 2012 · scored riskier than 20% of active trials completed
• Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin NCT03161132 · started 2017 · scored riskier than 81% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.